TY - JOUR
T1 - Infection with SARS-CoV-2 among children with asthma
T2 - evidence from Global Asthma Network
AU - GAN COVID Study Group
AU - Chiang, Chen-Yuan
AU - Ellwood, Philippa
AU - Ellwood, Eamon
AU - García-Marcos, Luis
AU - Masekela, Refiloe
AU - Asher, Innes
AU - Badellino, Héctor
AU - Sanz, Alberto Bercedo
AU - Douros, Konstantinos
AU - El Sony, Asma
AU - Diaz, Carlos González
AU - Rodríguez, Ms Albi
AU - Moreno-Salvador, Ana
AU - Pérez-Martini, Luis F
AU - Filho, Nelson Rosário
AU - Shpakou, Andrei
AU - Sulaimanov, Shairbek
AU - Tavakol, Marzieh
AU - Valverde-Molina, José
AU - Yousef, Abdullah A
AU - Pearce, Neil
N1 - © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
PY - 2022/1
Y1 - 2022/1
N2 - BACKGROUND: Clinical presentations of coronavirus disease 2019 (COVID-19) among children with asthma have rarely been investigated. This study aimed to assess clinical manifestations and outcome of COVID-19 among children with asthma, and whether the use of asthma medications was associated with outcomes of interest.METHODS: The Global Asthma Network (GAN) conducted a global survey among GAN centers. Data collection was between November 2020 and April 2021.RESULTS: Fourteen GAN centers from 10 countries provided data on 169 children with asthma infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was asymptomatic in 58 (34.3%), mild in 93 (55.0%), moderate in 14 (8.3%), and severe/critical in 4 (2.4%). Thirty-eight (22.5%) patients had exacerbation of asthma and 21 (12.4%) were hospitalized for a median of 7 days (interquartile range 3-16). Those who had moderate or more severe COVID-19 were significantly more likely to have exacerbation of asthma as compared to those who were asymptomatic or had mild COVID-19 (adjusted odds ratio (adjOR) 3.97, 95% CI 1.23-12.84). Those who used inhaled bronchodilators were significantly more likely to have a change of asthma medications (adjOR 2.39, 95% CI 1.02-5.63) compared to those who did not. Children who used inhaled corticosteroids (ICS) did not differ from those who did not use ICS with regard to being symptomatic, severity of COVID-19, asthma exacerbation, and hospitalization.CONCLUSIONS: Over dependence on inhaled bronchodilator may be inappropriate. Use of ICS may be safe and should be continued in children with asthma during the pandemic of COVID-19.
AB - BACKGROUND: Clinical presentations of coronavirus disease 2019 (COVID-19) among children with asthma have rarely been investigated. This study aimed to assess clinical manifestations and outcome of COVID-19 among children with asthma, and whether the use of asthma medications was associated with outcomes of interest.METHODS: The Global Asthma Network (GAN) conducted a global survey among GAN centers. Data collection was between November 2020 and April 2021.RESULTS: Fourteen GAN centers from 10 countries provided data on 169 children with asthma infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was asymptomatic in 58 (34.3%), mild in 93 (55.0%), moderate in 14 (8.3%), and severe/critical in 4 (2.4%). Thirty-eight (22.5%) patients had exacerbation of asthma and 21 (12.4%) were hospitalized for a median of 7 days (interquartile range 3-16). Those who had moderate or more severe COVID-19 were significantly more likely to have exacerbation of asthma as compared to those who were asymptomatic or had mild COVID-19 (adjusted odds ratio (adjOR) 3.97, 95% CI 1.23-12.84). Those who used inhaled bronchodilators were significantly more likely to have a change of asthma medications (adjOR 2.39, 95% CI 1.02-5.63) compared to those who did not. Children who used inhaled corticosteroids (ICS) did not differ from those who did not use ICS with regard to being symptomatic, severity of COVID-19, asthma exacerbation, and hospitalization.CONCLUSIONS: Over dependence on inhaled bronchodilator may be inappropriate. Use of ICS may be safe and should be continued in children with asthma during the pandemic of COVID-19.
KW - Adrenal Cortex Hormones/therapeutic use
KW - Asthma/drug therapy
KW - COVID-19
KW - Child
KW - Humans
KW - Pandemics
KW - SARS-CoV-2
U2 - 10.1111/pai.13709
DO - 10.1111/pai.13709
M3 - Article
C2 - 34856034
SN - 0905-6157
VL - 33
SP - e13709
JO - Pediatric Allergy and Immunology
JF - Pediatric Allergy and Immunology
IS - 1
ER -